Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 15.1.2018 | EN | Official Journal of the European Union | C 13/14 |

---

Judgment of the General Court of 20 November 2017 — Stada Arzneimittel v EUIPO — Urgo recherche innovation et développement (Immunostad)

(Case T-403/16)[(1)](#ntr1-C_2018013EN.01001401-E0001)

((EU trade mark - Invalidity proceedings - Application for the EU word mark Immunostad - Earlier national word mark ImmunoStim - Relative ground for refusal - Similarity of the trade marks - Likelihood of confusion - Article 8(1)(b) and Article 53(1)(a) of Regulation (EC) No 207/2009 (now Article 8(1)(b) and Article 60(1)(a) of Regulation (EU) 2017/1001) - Non-negligible part of the relevant public - Obligation to state reasons - Article 75 of Regulation No 207/2009 (now Article 94 of Regulation 2017/1001)))

(2018/C 013/23)

Language of the case: English

Parties

Applicant: Stada Arzneimittel AG (Bad Vilbel, Germany) (represented by: R. Kaase and J.-C. Plate, lawyers)

Defendant: European Union Intellectual Property Office (represented by: initially, D. Botis and, subsequently, D. Walicka, acting as Agents)

Other party to the proceedings before EUIPO, intervener before the General Court: Urgo recherche innovation et développement, formerly Société de développement et de recherche industrielle, then Vivatech (Chenôve, France) (represented by: A. Sion and A. Delafond-Nielsen, lawyers)

Re:

Action brought against the decision of the Fifth Board of Appeal of EUIPO of 19 April 2016 (Case R 863/2015-5), relating to invalidity proceedings between Vivatech and Stada Arzneimittel.

Operative part of the judgment

The General Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Stada Arzneimittel AG to pay the costs. |

---

[Top](#document1)